We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$4B 32.41%
34,230,323
+100,162
+0.3% +$12.7M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.49B 20.18%
45,725,556
– –
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.2B 9.73%
8,553,864
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.08B
$973M 7.89%
25,819,768
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12.9B
$550M 4.46%
5,905,673
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$442M 3.59%
13,780,480
+614
+0% +$19.4K
ONC
7
BeOne Medicines Ltd
ONC
$42.4B
$403M 3.27%
3,898,431
+225,256
+6% +$16.8M
DBVT
8
DBV Technologies
DBVT
$914M
$234M 1.9%
550,956
– –
NGNE icon
9
Neurogene
NGNE
$773M
$155M 1.26%
546,708
– –
AAAP
10
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$152M 1.23%
2,243,262
+21,556
+1% +$1.05M
ONCE
11
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$123M 1%
1,384,130
+65,789
+5% +$5M
ASND icon
12
Ascendis Pharma A/S
ASND
$16.6B
$85.1M 0.69%
2,348,840
+597,377
+34% +$17.1M
AMRN
13
Amarin Corp
AMRN
$298M
$79.3M 0.64%
1,133,475
– –
AVXS
14
DELISTED
AveXis, Inc. Common Stock
AVXS
$75M 0.61%
775,000
+150,000
+24% +$13.5M
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.44B
$73.3M 0.59%
13,997,172
+2,280,388
+19% +$11.7M
NVTA
16
DELISTED
Invitae Corporation
NVTA
$68.3M 0.55%
7,288,300
– –
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$64.1M 0.52%
5,213,528
+3,627,615
+229% +$33.7M
AKAO
18
DELISTED
Achaogen Inc
AKAO
$62M 0.5%
3,886,878
-917,726
-19% -$17.5M
BLCM
19
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$58.1M 0.47%
503,231
– –
EXEL icon
20
Exelixis
EXEL
$13.4B
$50.4M 0.41%
2,082,012
– –
HRTX icon
21
Heron Therapeutics
HRTX
$60.4M
$45M 0.37%
2,787,992
+4,423
+0.2% +$69.4K
NBIX icon
22
Neurocrine Biosciences
NBIX
$15.5B
$37.8M 0.31%
616,682
– –
BLUE
23
DELISTED
bluebird bio
BLUE
$33.2M 0.27%
18,639
-4,632
-20% -$6.47M
SGMO
24
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$31.7M 0.26%
2,113,376
-2,000,000
-49% -$22.1M
ABEO icon
25
Abeona Therapeutics
ABEO
$348M
$28.7M 0.23%
67,375
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2017 Portfolio in Review

As of Q3 2017, Julian Baker held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Julian Baker added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Julian Baker's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Julian Baker fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Julian Baker's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Julian Baker opened 9 new positions and closed 9 in Q3 2017.
  • Julian Baker's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.